These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38069339)

  • 1. PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets.
    Puertas-Umbert L; Alonso J; Hove-Madsen L; Martínez-González J; Rodríguez C
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling.
    Houslay MD; Baillie GS; Maurice DH
    Circ Res; 2007 Apr; 100(7):950-66. PubMed ID: 17431197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.
    Zhao CY; Greenstein JL; Winslow RL
    J Mol Cell Cardiol; 2015 Nov; 88():29-38. PubMed ID: 26388264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
    Netherton SJ; Maurice DH
    Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
    Houslay MD; Adams DR
    Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
    Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
    Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational investigation of the dynamic control of cAMP signaling by PDE4 isoform types.
    Paes D; Hermans S; van den Hove D; Vanmierlo T; Prickaerts J; Carlier A
    Biophys J; 2022 Jul; 121(14):2693-2711. PubMed ID: 35717559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of cyclic nucleotide phosphodiesterases in the cAMP compartmentation in cardiac cells].
    Mika D; Leroy J; Vandecasteele G; Fischmeister R
    Biol Aujourdhui; 2012; 206(1):11-24. PubMed ID: 22463992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.
    Wang L; Burmeister BT; Johnson KR; Baillie GS; Karginov AV; Skidgel RA; O'Bryan JP; Carnegie GK
    Cell Signal; 2015 May; 27(5):908-22. PubMed ID: 25683917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE4: arrested at the border.
    Brunton LL
    Sci STKE; 2003 Oct; 2003(204):PE44. PubMed ID: 14560046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo.
    Tilley DG; Maurice DH
    Mol Pharmacol; 2002 Sep; 62(3):497-506. PubMed ID: 12181425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reciprocal regulation of calcium dependent and calcium independent cyclic AMP hydrolysis by protein phosphorylation.
    Ang KL; Antoni FA
    J Neurochem; 2002 May; 81(3):422-33. PubMed ID: 12065651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
    Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.
    Kerfant BG; Zhao D; Lorenzen-Schmidt I; Wilson LS; Cai S; Chen SR; Maurice DH; Backx PH
    Circ Res; 2007 Aug; 101(4):400-8. PubMed ID: 17615371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches.
    Lugnier C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple cAMP Phosphodiesterases Act Together to Prevent Premature Oocyte Meiosis and Ovulation.
    Vigone G; Shuhaibar LC; Egbert JR; Uliasz TF; Movsesian MA; Jaffe LA
    Endocrinology; 2018 May; 159(5):2142-2152. PubMed ID: 29608743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals.
    Abi-Gerges A; Richter W; Lefebvre F; Mateo P; Varin A; Heymes C; Samuel JL; Lugnier C; Conti M; Fischmeister R; Vandecasteele G
    Circ Res; 2009 Oct; 105(8):784-92. PubMed ID: 19745166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.
    Murthy KS; Zhou H; Makhlouf GM
    Am J Physiol Cell Physiol; 2002 Mar; 282(3):C508-17. PubMed ID: 11832336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.